Projects
We explore the frontiers of immunoengineering to create innovative therapies that transform human health. Our work targets immune regulation, aiming to enhance cancer treatment and promote tissue regeneration. Leveraging interdisciplinary approaches that integrate biomaterials, nanomedicine, and immunology, we design cutting-edge technologies to reprogram the tumor microenvironment, develop personalized cancer nanovaccines, and engineer immunomodulatory scaffolds for musculoskeletal repair. Through these projects, we strive to translate fundamental discoveries into practical solutions, advancing therapies that precisely harness the immune system to fight disease and restore damaged tissues.
Illustrations created with BioRender.com
Tumor Microenvironment Reprogramming
We design nano- and biomaterial-based strategies to activate adaptive T cell immunity and repolarize immunosuppressive macrophages, enhancing the efficacy of chemo-, radio-, and immunotherapy. This approach aims to remodel the tumor microenvironment to improve therapeutic outcomes and potentiate antitumor immune responses.
Illustrations created with BioRender.com
Personalized Cancer Nanovaccines
We develop tailored nanovaccine platforms that co-deliver neoantigen peptides and TLR agonists alongside checkpoint inhibitors (anti-PD-1 and anti-CTLA-4) to amplify T cell-mediated antitumor activity. These vaccines aim to provide highly specific, patient-centered immunotherapy for durable cancer control.
Illustrations created with BioRender.com
Immunoengineering for Musculoskeletal Tissue Repair
We engineer biodegradable scaffolds that synergistically enhance bone regeneration by optimizing osteoinductivity, osteoconductivity, and mechanical strength while incorporating immunomodulatory strategies. By promoting regulatory T cell activity, these scaffolds guide the immune environment to support efficient tissue repair and functional recovery.
Targeted Tumor Microbiome Modulation
We develop smart biomaterials that respond to tumor microenvironment cues (hypoxia, pH, enzymes, redox) to selectively deliver antibacterials targeting tumor-associated bacteria. Our platform enables flexible targeting of pathogenic bacterial populations to reduce immunosuppression and therapy resistance across multiple cancer types.
.png)